United States· US:0002-4178_eac65e03-3444-4d6b-acb8-ea4f7a276f03
FOUNDAYO
A medicinal product containing orforglipron calcium, registered in United States by Eli Lilly and Company.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ORFORGLIPRON CALCIUM
- Manufacturer
- Eli Lilly and Company
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 9, 2026
Packs & prices · 4
- ndc1100024178311 BOTTLE in 1 CARTON (0002-4178-31) / 30 TABLET, FILM COATED in 1 BOTTLE (0002-4178-01)
- ndc1100024178621 BOTTLE in 1 CARTON (0002-4178-62) / 30 TABLET, FILM COATED in 1 BOTTLE
- ndc110002-4178-31
- ndc110002-4178-62
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d0bba237-f4af-40e2-819a-89d69dd92596 GET /v1/drugs/d0bba237-f4af-40e2-819a-89d69dd92596?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": ".8",
"substance": "ORFORGLIPRON CALCIUM",
"productndc": "0002-4178",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA220934",
"marketing_category": "NDA"
}See everything about orforglipron calcium.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.